Sanofi (SNY)

NASDAQ: SNY · Real-Time Price · USD
50.90
+0.76 (1.52%)
At close: Oct 3, 2025, 4:00 PM EDT
50.27
-0.63 (-1.24%)
After-hours: Oct 3, 2025, 7:11 PM EDT
1.52%
Market Cap124.04B
Revenue (ttm)53.71B
Net Income (ttm)10.72B
Shares Out 1.22B
EPS (ttm)8.65
PE Ratio11.57
Forward PE10.81
Dividend$1.60 (3.14%)
Ex-Dividend DateMay 9, 2025
Volume3,729,615
Open50.37
Previous Close50.14
Day's Range50.33 - 51.05
52-Week Range44.62 - 60.12
Beta0.44
AnalystsBuy
Price Target61.50 (+20.83%)
Earnings DateOct 24, 2025

About SNY

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]

Sector Healthcare
Founded 1994
Employees 82,878
Stock Exchange NASDAQ
Ticker Symbol SNY
Full Company Profile

Financial Performance

In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.

Financial numbers in EUR Financial Statements

Analyst Summary

According to 4 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $61.5, which is an increase of 20.83% from the latest price.

Price Target
$61.5
(20.83% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Sanofi: Undervalued 2026 Pipeline, And Solid Results (Rating Upgrade)

Sanofi is repositioned as a pure pharma play. Following an earnings reset, we see support in ongoing buybacks and higher sales guidance. Q2 results showed strong Dupixent growth, and 2026 readouts off...

13 hours ago - Seeking Alpha

Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with s...

Other symbols: RVTY
3 days ago - Business Wire

QuantHealth Secures Strategic Investment from Sanofi Ventures to Accelerate AI-Driven Clinical Trials

TEL AVIV, Isreal & CAMBRIDGE, Mass.--(BUSINESS WIRE)--QuantHealth, a pioneer in AI-driven clinical trial simulation, announced a strategic investment from Sanofi Ventures, the venture capital arm of g...

4 days ago - Business Wire

A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff

Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products pu...

Other symbols: AZNLLYNVO
9 days ago - Seeking Alpha

Sanofi Expands Insulin Savings Program To Cover All US Patients

The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA's (NASDAQ: S...

9 days ago - Benzinga

Sanofi to offer all insulin products for $35 per month in US

French drugmaker Sanofi said on Friday it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status.

9 days ago - Reuters

Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US

MORRISTOWN, N.J. , Sept. 26, 2025 /PRNewswire/ -- Sanofi US today announces a broad expansion of its Insulins Valyou Savings Program by offering a 30-day supply of any Sanofi insulin for $35 to all pa...

9 days ago - PRNewsWire

French court orders Sanofi to pay $177 million for anti-competitive behaviour

A Paris court on Wednesday ordered Sanofi and its Winthrop unit to pay 150.7 million euros ($177.1 million) in damages to France's national health insurance fund (CNAM) for anti-competitive practices ...

11 days ago - Reuters

Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation

Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation The fund will remain focused on Sanofi's key areas of immunology, rare di...

11 days ago - GlobeNewsWire

Press release: Availability of the Q3 2025 Aide mémoire

Availability of the Q3 2025 Aide mémoire Paris, France – September 24, 2025. Sanofi announced today that its Q3 2025 Aide mémoire is available on the "Investors" page of the company's website: Third q...

11 days ago - GlobeNewsWire

Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Other symbols: SAN
12 days ago - Seeking Alpha

Press Release: Sanofi's SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1

Sanofi's SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, designed to silence DMPK ex...

12 days ago - GlobeNewsWire

Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis

Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis Paris, September 22, 2025. The US Food and Drug Administration (FDA) has extended by three...

13 days ago - GlobeNewsWire

Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion

Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent sig...

Other symbols: REGN
13 days ago - GlobeNewsWire

Press Release: EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study

EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary e...

18 days ago - GlobeNewsWire

Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration

Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate t...

24 days ago - GlobeNewsWire

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...

25 days ago - Reuters

Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®

Mandy Moore joins Elaine Welteroth, Gaby Dalkin, Katya Echazarreta, and Shawn Johnson East to share their personal respiratory syncytial virus (RSV) stories and why they chose BEYFORTUS to help protec...

25 days ago - PRNewsWire

Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes

Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes

25 days ago - GlobeNewsWire

Sanofi (SNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sanofi (NASDAQ:SNY) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT Company Participants Paul Hudson - CEO & Director Conference Call Participants Sarita Kapila ...

26 days ago - Seeking Alpha

Sanofi market value tanks following weak results on eczema drug trials

Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after late-stage trial data for its experimental inflammatory disease drug amlitelimab...

4 weeks ago - Fast Company

Why Is Sanofi Stock Falling Thursday?

On Thursday, Sanofi SA SNY stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fre...

4 weeks ago - Benzinga

Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors

French drugmaker Sanofi SA SNY stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expecta...

4 weeks ago - Benzinga

Sanofi Shares Sink as Experimental Drug Results Disappoint

Sanofi shares plunged at the market open Thursday as results from a late-stage trial of its experimental drug to treat skin conditions disappointed investors.

4 weeks ago - Market Watch

Sanofi shares sink over 9% on weak trial results for experimental inflammation drug

Shares in French drugmaker Sanofi fell more than 9% on Thursday after late-stage trial data for its experimental inflammatory disease drug amlitelimab fell short of Wall Street expectations.

4 weeks ago - Reuters